Bevacizumab: all 1,786 studies that test it
Page 18 of 18. Open to participants first (285), then studies with results posted, then the rest; newest registration first within each.
- Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory GliomasCompletedNCT00268359Phase 2
- Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)CompletedNCT00265824Phase 3
- Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic CancerCompletedNCT00260364Phase 1/2
- Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00255762Phase 2
- Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT00254319Phase 2
- Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic CancerWithdrawnNCT00253526Phase 2
- A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLCCompletedNCT00251524Phase 2
- Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic CancerCompletedNCT00222469Phase 2
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
- Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung CancerCompletedNCT00217282Phase 2
- A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and NeckCompletedNCT00203905Phase 2
- Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
- OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00193154Phase 2
- Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)Status unknownNCT00184015Phase 1/2
- Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal CancerCompletedNCT00165568Phase 2
- Bevacizumab in Advanced Hepatocellular CarcinomaStatus unknownNCT00162669Phase 2
- Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung CancerStatus unknownNCT00150657Phase 2
- Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder CancerCompletedNCT00142480Phase 2
- Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular CarcinomaCompletedNCT00142467Phase 2
- Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic MelanomaCompletedNCT00139360Phase 2
- Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated MesotheliomaCompletedNCT00137826Phase 2
- Avastin and Taxotere for Esophagogastric CancerCompletedNCT00137813Phase 2
- Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine TumorsCompletedNCT00137774Phase 2
- Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma PatientsCompletedNCT00127920Phase 2
- Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00126633Phase 2
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
- Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal CancerTerminatedNCT00120172Phase 2
- Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal CancerCompletedNCT00118261Phase 1
- Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerCompletedNCT00118235Phase 2
- S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal CancerWithdrawnNCT00118105Phase 2
- Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2
- A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal CancerTerminatedNCT00114946Phase 4
- Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00114179Phase 2
- Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00112528Phase 2
- A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerCompletedNCT00109239Phase 3
- A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedNCT00109226Phase 2
- A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal CancerCompletedNCT00109070Phase 3
- An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00109057Phase 2
- Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
- A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has FailedCompletedNCT00097019Phase 2
- A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00096967Phase 3
- Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
- Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)CompletedNCT00095706Phase 1/2
- BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid TumorsCompletedNCT00095459Phase 1
- A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00095225Phase 2
- Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast CancerCompletedNCT00088998Phase 2
- Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00088894Phase 3
- Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
- Bevacizumab in Treating Young Patients With Refractory Solid TumorsCompletedNCT00085111Phase 1
- Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00084604Phase 2
- Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast CancerCompletedNCT00083031Phase 2
- A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell CarcinomaCompletedNCT00081614Phase 2
- Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
- Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00072046Phase 3
- Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard ChemotherapyCompletedNCT00066846Phase 2
- Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal CancerCompletedNCT00062426Phase 3
- Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell CarcinomaWithdrawnNCT00061178Phase 3
- A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerCompletedNCT00060411Phase 1
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00055913Phase 1/2
- Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast CancerCompletedNCT00055861Phase 2
- Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsCompletedNCT00055809Phase 2
- Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal CancerCompletedNCT00052559Phase 1
- Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue SarcomaCompletedNCT00052390Phase 2
- Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal CancerCompletedNCT00047762Phase 1
- Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic CancerCompletedNCT00047710Phase 1
- Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00043823Phase 1/2
- Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal CancerTerminatedNCT00043004Phase 2
- Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00028990Phase 3
- Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic CancerCompletedNCT00028834Phase 2
- Phase II Bevacizumab + Tax In Advanced Breast CancerCompletedNCT00027885Phase 2
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaCompletedNCT00027703Phase 2
- APC8015 and Bevacizumab in Treating Patients With Prostate CancerCompletedNCT00027599Phase 2
- Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung CancerCompletedNCT00025389Phase 2
- Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously TreatedCompletedNCT00025337Phase 3
- Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
- Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
- Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00022607Phase 2
- Bevacizumab in Treating Patients With Myelodysplastic SyndromeCompletedNCT00022048Phase 1/2
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung CancerCompletedNCT00021060Phase 2/3
- Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerCompletedNCT00017394Phase 2
- Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast CancerCompletedNCT00016549Phase 2
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate CancerCompletedNCT00016107Phase 2
- S0108 Bevacizumab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00016094Phase 2
- Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic CancersCompletedNCT00015951Phase 2
- Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal CancerCompletedNCT00006786Phase 2
- Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00005061Phase 1